Effects of Recombinant Human Soluble Thrombomodulin (rhs-TM) on a Rat Model of Disseminated Intravascular Coagulation with Decreased Levels of Plasma Antithrombin III

Summary

We reported that recombinant human soluble thrombomodulin (rhs- TM) is effective for disseminated intravascular coagulation (DIC) in vivo, in mice and rats. In the present work, we investigated the effects of decreased plasma antithrombin III (ATIII) levels on anticoagulant effects of rhs-TM, as compared to findings with heparin, of which effect is lowered by the decreased plasma ATIII levels in patients with DIC. Rat plasma ATIII levels decreased when we mixed plasma with anti-rat ATIII antibody and the potential of heparin to prolong APTT or PT was markedly diminished. The potential of rhs-TM to prolong APTT and PT was not affected. In rats injected with anti-rat ATIII antibody, plasma ATIII levels decreased immediately. When the rats were infused with tissue factor (TF), DIC was induced. At doses of rhs-TM and heparin which were equally effective at inhibiting the decrease in platelet count and fibrinogen level in cuntiol rats treated with TF, only rhs-TM remained effective in preventing DIC in rats with reduced ATIII levels. Heparin was not effective, when administered to these rats with reduced ATIII levels. Therefore, rhs-TM effectively inhibits coagulation independent of ATIII levels, in contrast to heparin, which depends on the ATIII level.

• References

• 1 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6
• 2 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257: 7944-7
• 3 Esmon NL, Owen WG, Esmon CT. Isolation of a membranebound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-64
• 4 Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258: 12238-12
• 5 Esmon CT. Protein-C: Biochemistry, physiology, and clinical implications. Blood 1983; 62: 1155-8
• 6 Marlar RA, Kieiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thromhin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-72
• 7 Suzuki K, Stenflo J, Dahlback B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914-20
• 8 Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987 6: 1891-7
• 9 Shirai T, Shiojiri S, Ito H, Yamamoto S, Kusumoto H, Deyashiki Y, Maruyama I, Suzuki K. Gene structure of human thrombomodulin, a cofactor for thrombin-catalyzed activation of protein C. J Biochem 1988; 103: 281-5
• 10 Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Kanabayashi T, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-9
• 11 Gonda Y, Hirata S, Saitoh K, Aoki Y, Mohri M, Gomi K, Sugihara T, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats. Thromb Res 1993; 71: 325-35
• 12 Aritomi M, Watanabe N, Ohishi R, Gomi K, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: thrombomodulin associates with free thrombin and is recycled to activate protein C. Thromb Haemostas 1993; 70: 418-22
• 13 Ohishi R, Watanabe N, Aritomi M, Gomi K, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Evidence that a protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma. Thromb Haemostas 1993; 70: 423-6
• 14 Rosenberg RD, Damus P. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505
• 15 Nakagawa M, Tsuiji H, Maebo N, Toyoda T, Sawada S, Takamatsu H, Ijichi H. Congenital and acquired antithrombin III deficiency. Acta Haematol Jpn 1985; 48: 1885-94
• 16 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematology 1981; 10: 369-90
• 17 Wessler S, Gitel SN. Pharmacology of heparin and warfarin. JACC 1986; 8: 10B-20B
• 18 Spero JA, Lewis JH, Hasiba U. Disseminated Intravascular Coagulation. Findings in 346 patients. Thromb Haemostas 1980; 43: 28-33
• 19 Bick RL, Dukes ML, Wilson WL, Fekete LF. Antithrombin III (AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res 1977; 10: 721-9
• 20 Schipper HG, Jenkins CP, Kahle LH, ten Cate JW. Antithrombin-III transfusion in disseminated intravascular coagulation. Lancet 1978 22: 854-6
• 21 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with “New” chromogenic substrates (S-2238 and CHROMOZYM TH). Thromb Res 1977; 11: 549-53
• 22 Tsuji H. Antithrombin III. Jpn J Clin Hematol 1990; 31: 750-5
• 23 Kumada T, Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin Ill-deficient animals. Thromb Res 1981; 24: 285-98
• 24 Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985; 66: 59-63
• 25 Takahashi H, Hanano M, Takizawa S, Takewaki W, Fuse I, Satoh K, Wada K, Shibata A. Serial changes in protein C, antithrombin III, α₂-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC). Jpn J Clin Hematol 1988; 29: 336-43
• 26 Nawa K, Itani T, Ono M, Sakano K, Marumoto Y, Iwamoto M. The glycosaminoglycan of recombinant hitman soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation. Thromb Haemostas 1992; 67: 366-70